Back

JBT101-DM-002

Official Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Study Details

The purpose of this study is to investigate the efficacy and safety of lenabasum in participants with dermatomyositis.

Principal Investigator

Dr. Heather Jones

IRB Number

201812065

Eligibility

Inclusion:
1. Participants must be 18 years of age or older.
2. Participants must have a history of dermatomyositis with current active disease.
3. Participants must be willing to not use any cannabinoids, including recreational marijuana, medical marijuana and other prescription cannabinoids from screening through end of study.
4. Participants must not have unstable dermatomyositis or end-stage organ involvement and must not have history of cancer (except for treated basal or squamous cell carcinoma of the skin or cervical carcinoma in situ) within 3 years of enrollment.

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back